Growth Hormone Deficiency Market Size, Share, Growth Analysis, By Brand, By Application, By End User, By Region - Industry Forecast 2024-2031

Growth Hormone Deficiency Market size was valued at USD 3.47 billion in 2022 and is poised to grow from USD 3.70 billion in 2023 to USD 6.12 billion by 2031, growing at a CAGR of 6.50% in the forecast period (2024-2031).

The increasing prevalence of growth hormone deficiency (GHD), caused by factors such as brain injuries, genetic disorders, congenital conditions, and specific medical treatments, has led to a rising demand for growth hormone therapies. According to the National Center for Biotechnology Information (NCBI), pediatric growth hormone deficiency affects approximately 1 in every 3,500-4,000 children in the United Kingdom. This rising incidence has driven industry growth, supported by intensified research and development efforts. A significant milestone occurred in February 2022 when Pfizer and OPKO received marketing authorization from the European Union for their Once-Weekly NGENLA(TM) (somatrogon) Injection, marking a notable advancement in the field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Growth Hormone Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Growth Hormone Deficiency Market Segmental Analysis

Growth Hormone Deficiency Market is segmented on the basis of brand, application and end user. Based on brand, the market is segmented into Norditropin, Genotropin, Humatrope, Saizen, and Omnitrope. Based on application, the market is segmented into Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others. Based on End User, it is bifurcated into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy. Based on region, it is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Drivers of the Growth Hormone Deficiency Market

Human growth hormone (HGH), also known as somatotropin, is crucial in human development as it promotes cell growth, division, and regeneration. Inadequate production of growth hormone (GH) by the pituitary gland results in hGH deficiency in humans. Treatment typically involves administering recombinant human growth hormone via subcutaneous injection. Genetic conditions like Prader-Willi syndrome and Turner syndrome, which are marked by delayed puberty and shorter stature, can also lead to insufficient growth hormone levels.

Restraints in the Growth Hormone Deficiency Market

The expenses linked with human growth hormone (HGH) therapy pose a significant obstacle, restricting access for many patients and posing challenges to healthcare systems. A 2022 study published in a medical journal underscored the substantial financial burden experienced by both patients and healthcare systems. This has drawn attention to the necessity for flexibility and potential adjustments in pricing. Achieving broad access to HGH treatment necessitates tackling the financial hurdles associated with its high cost.

Market Trends of the Growth Hormone Deficiency Market

The pharmaceutical sector is set for substantial expansion thanks to rapid advancements in drug delivery methods. Innovations like wearables, needle-free devices, and autoinjectors have played a pivotal role in enhancing comfort levels and patient adherence to growth hormone therapy. Particularly noteworthy are the swift development of long-acting drugs and implantable devices, which enable extended delivery periods and less frequent dosing of growth hormone. These advancements not only enhance clinical outcomes but also elevate the overall patient experience, thereby broadening the accessibility and effectiveness of growth hormone therapies.